Marleen Boelaert spends much of her time researching Visceral leishmaniasis, Leishmaniasis, Internal medicine, Immunology and Veterinary medicine. Marleen Boelaert studies Visceral leishmaniasis, namely Leishmania donovani. In the field of Leishmaniasis, her study on Miltefosine and Sodium stibogluconate overlaps with subjects such as Amphotericin B and Indian subcontinent.
Marleen Boelaert combines subjects such as Gastroenterology, Surgery and Pharmacology with her study of Internal medicine. Her Immunology study combines topics from a wide range of disciplines, such as Prospective cohort study, Asymptomatic and Pediatrics. Her Veterinary medicine research integrates issues from Epidemiology, Randomized controlled trial, Mass screening, Poverty and Socioeconomics.
The scientist’s investigation covers issues in Visceral leishmaniasis, Leishmaniasis, Immunology, Internal medicine and Leishmania donovani. Her Visceral leishmaniasis study incorporates themes from Veterinary medicine, Direct agglutination test, Surgery and Environmental health. Her Surgery study integrates concerns from other disciplines, such as Sodium stibogluconate and Pharmacotherapy.
Her Leishmaniasis study combines topics in areas such as Asymptomatic, Epidemiology and Incidence. Her Incidence research focuses on subjects like Public health, which are linked to Socioeconomics. Marleen Boelaert combines topics linked to Leishmania with her work on Immunology.
Marleen Boelaert focuses on Visceral leishmaniasis, Leishmaniasis, Public health, African trypanosomiasis and Internal medicine. Her Visceral leishmaniasis research incorporates elements of Demography, Incidence and Disease. Her Leishmaniasis research is multidisciplinary, relying on both Xenodiagnosis, Serology and Leishmania.
The study incorporates disciplines such as Sustainability, Process and Intensive care medicine in addition to Public health. Her study in the field of Trypanosoma brucei gambiense also crosses realms of Democracy. Her work in Internal medicine tackles topics such as Post-kala-azar dermal leishmaniasis which are related to areas like Multivariate analysis.
Her primary scientific interests are in Visceral leishmaniasis, Leishmaniasis, Public health, Disease and Epidemiology. Her research integrates issues of Internal medicine, Asymptomatic and Demography in her study of Visceral leishmaniasis. Her work on Leishmania donovani as part of general Leishmaniasis study is frequently linked to Molecular epidemiology, therefore connecting diverse disciplines of science.
Her studies in Public health integrate themes in fields like Psychosocial, Sustainability, Socioeconomics and Cutaneous leishmaniasis. Her Disease research is multidisciplinary, incorporating elements of Poverty and Surgery. Marleen Boelaert interconnects Environmental health, Buruli ulcer, Gold standard, African trypanosomiasis and Histopathology in the investigation of issues within Epidemiology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?
François Chappuis;François Chappuis;Shyam Sundar;Asrat Hailu;Hashim Ghalib.
Nature Reviews Microbiology (2007)
Visceral leishmaniasis : current status of control, diagnosis, and treatment, and a proposed research and development agenda
Philippe J Guerin;Philippe J Guerin;Piero Olliaro;Piero Olliaro;Shyam Sundar;Marleen Boelaert.
Lancet Infectious Diseases (2002)
Spread of Vector-borne Diseases and Neglect of Leishmaniasis, Europe
Jean-Claude Dujardin;Lenea Campino;Carmen Cañavate;Jean-Pierre Dedet.
Emerging Infectious Diseases (2008)
Control of visceral leishmaniasis in latin america-a systematic review.
Gustavo A. S. Romero;Marleen Boelaert.
PLOS Neglected Tropical Diseases (2010)
Kashin–Beck Osteoarthropathy in Rural Tibet in Relation to Selenium and Iodine Status
Rodrigo Moreno-Reyes;Carl Suetens;Françoise Mathieu;Françoise Begaux.
The New England Journal of Medicine (1998)
Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis
Caryn Bern;Jill Adler-Moore;Juan Berenguer;Marleen Boelaert.
Clinical Infectious Diseases (2006)
Combination therapy for visceral leishmaniasis
Johan van Griensven;Manica Balasegaram;Filip Meheus;Jorge Alvar.
Lancet Infectious Diseases (2010)
A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis
François Chappuis;Suman Rijal;Alonso Soto;Joris Menten.
Increasing Failure of Miltefosine in the Treatment of Kala-azar in Nepal and the Potential Role of Parasite Drug Resistance, Reinfection, or Noncompliance
Suman Rijal;Bart Ostyn;Surendra Uranw;Surendra Uranw;Keshav Rai.
Clinical Infectious Diseases (2013)
Recurrence in tuberculosis: relapse or reinfection?
Marie-Laurence Lambert;Epco Hasker;Armand Van Deun;Dominique Roberfroid.
Lancet Infectious Diseases (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: